Results 1 to 10 of about 164,783 (254)

Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis [PDF]

Arquivos de Neuro-Psiquiatria, 2002
Depression and suicide have been reported in association with multiple sclerosis (MS). Some studies show that interferon beta may increase the depression rate.
Marco Aurélio Lana-Peixoto, Antônio Lúcio Teixeira Jr., Vitor Geraldi Haase   +2 more
doaj   +1 more source

Interferon Beta

, 2006
europepmc   +3 more sources

Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis

EClinicalMedicine, 2021
Background: The timing of administration of agents and use of combination treatments in COVID-19 remain unclear. We assessed the effectiveness of therapeutics in cohorts in Hong Kong SAR and Anhui, China.
Carlos K.H. Wong, Eric Y.F. Wan, Sihui Luo, Yu Ding, Eric H.Y. Lau, Ping Ling, Xiaowen Hu, Edward C.H. Lau, Jerry Wong, Xueying Zheng, Benjamin J. Cowling, Jianping Weng, Gabriel M. Leung   +12 more
doaj   +1 more source

Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients [PDF]

Arquivos de Neuro-Psiquiatria, 2006
Since 1993 the Federal Drug Administration approved the use of immunomodulatory therapy in multiple sclerosis (MS), modifying the natural course of disease, as demonstrate our experience in treatment of MS patients at the MS Treatment Center (CATEM ...
Charles Peter Tilbery, Maria Fernanda Mendes, Bianca Etelvina Santos de Oliveira, Rodrigo Barbosa Thomaz, Giorge Ribeiro Kelian   +4 more
doaj   +1 more source

Nowe perspektywy leczenia wtórnie postępującej postaci stwardnienia rozsianego

Aktualności Neurologiczne, 2015
Stwardnienie rozsiane jest przewlekłą autoimmunologiczną chorobą ośrodkowego układu nerwowego o nieznanej przyczynie i zmiennym przebiegu. W około 85% przypadków najpierw występuje postać rzutowo-remisyjna, która po pewnym czasie (różniącym się w ...
Magdalena Noga, Halina Bartosik-Psujek
doaj   +1 more source

Validation of a test procedure for determination of specific activity of human recombinant interferon beta (Infibeta®) using various cell/virus combinations

Биопрепараты: Профилактика, диагностика, лечение, 2022
Interferon beta preparations have demonstrated efficacy in the treatment of multiple sclerosis. One of the most important quality attributes that support efficacy and safety of interferon beta preparations is specific antiviral activity.
Yu. N. Lebedeva, N. A. Litvinova, T. N. Lobanova, R. R. Shukurov, R. A. Khamitov, L. A. Gaiderova   +5 more
doaj   +1 more source

Erupção acneiforme aguda induzida por interferon beta-1b durante tratamento para esclerose múltipla Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis

Anais Brasileiros de Dermatologia, 2011
Esclerose múltipla é uma doença inflamatória desmielinizante, com presumida origem autoimune, que afeta o sistema nervoso central. A principal modalidade terapêutica é baseada no uso de imunomoduladores, como o interferon beta, que são geralmente bem ...
Dário Júnior de Freitas Rosa, Fernanda de Abreu Toledo Matias, Sâmya Diégues Cedrim, Ronaldo Figueiredo Machado, Alessandra Almeida Montenegro de Sá, Vânia Carolina Piccinini Silva   +5 more
doaj   +1 more source

Fuzzy Logic System for Classifying Multiple Sclerosis Patients as High, Medium, or Low Responders to Interferon-Beta

Technologies, 2023
Interferon-beta is one of the most widely prescribed disease-modifying therapies for multiple sclerosis patients. However, this treatment is only partially effective, and a significant proportion of patients do not respond to this drug.
Edgar Rafael Ponce de Leon-Sanchez, Jorge Domingo Mendiola-Santibañez, Omar Arturo Dominguez-Ramirez, Ana Marcela Herrera-Navarro, Alberto Vazquez-Cervantes, Hugo Jimenez-Hernandez, Horacio Senties-Madrid   +6 more
doaj   +1 more source

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

BMC Neurology, 2019
Background Interferon (IFN) beta drugs have been approved for the treatment of relapsing forms of multiple sclerosis (RMS) for more than 20 years and are considered to offer a favourable benefit-risk profile. In July 2014, subcutaneous (SC) peginterferon
Annette Kolb-Mäurer, Cord Sunderkötter, Borries Kukowski, Sven G. Meuth, on behalf of the members of an expert meeting   +4 more
doaj   +1 more source

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

BMC Health Services Research, 2020
Background To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level.
Marcello Moccia, Ilaria Loperto, Roberta Lanzillo, Antonio Capacchione, Antonio Carotenuto, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino   +7 more
doaj   +1 more source